<DOC>
	<DOCNO>NCT00301834</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , fludarabine busulfan , work different way stop growth cancer cell , either kill cell stop dividing . A peripheral stem cell , bone marrow , umbilical cord blood transplant may able replace blood-forming cell destroy chemotherapy . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine together methotrexate methylprednisolone may stop happen . PURPOSE : This phase II trial study well give alemtuzumab together fludarabine busulfan work give donor stem cell transplant treat young patient hematologic disorder .</brief_summary>
	<brief_title>Alemtuzumab , Fludarabine , Busulfan Followed By Donor Stem Cell Transplant Treating Young Patients With Hematologic Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine engraftment rate reduce toxicity ablative conditioning regimen comprise alemtuzumab , fludarabine , busulfan follow allogeneic stem cell transplantation pediatric patient stem cell defect , marrow failure syndrome , hemoglobinopathy , severe immunodeficiency syndrome ( nonsevere combine immunodeficiency disorder ) , myelodysplastic syndrome , myeloid leukemia . Secondary - Determine acute reaction , incidence infection , rate immune reconstitution patient treat regimen . OUTLINE : This multicenter study . - Conditioning regimen : Patients receive alemtuzumab IV 6 hour day -12 -10 , high-dose busulfan IV 2 hour 4 time daily day -9 -6 , fludarabine IV 30 minute day -5 -2 . - Allogeneic stem cell transplantation : Two day completion condition regimen , patient undergo allogeneic bone marrow , peripheral blood stem cell , umbilical cord blood transplantation day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 5 continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : - Most transplantation ( bone marrow peripheral blood stem cell transplantation ) : Patients receive cyclosporine IV continuously begin day -1 least day 50 follow taper either 2 month , 9 month , 1 year absence GVHD . Patients also receive methotrexate day 1 , 3 , 6 . - Umbilical cord blood transplantation : Patients receive cyclosporine transplantation , methylprednisolone IV twice daily day 0-21 followed weekly taper . After transplantation , patient follow periodically 20 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic condition : Aplastic anemia marrow aplasia , meet follow criterion : Absolute neutrophil count &lt; 500/mm^3 Platelet and/or red cell transfusion dependent Chronic aplastic anemia , meet follow criterion : Transfusion dependent Unresponsive immunosuppressive therapy Alternative match unrelated donor identify Congenital marrow failure syndrome , include follow ( closely match relate unrelated donor ) : Primary red cell aplasia ( DiamondBlackfan syndrome ) Congenital neutropenia ( Kostmann 's syndrome ) Amegakaryocytic thrombocytopenia Congenital dyserythropoietic anemia Other severe acquire cytopenias transplantation use combine busulfan/cyclophosphamide condition regimen indicate Hemoglobinopathy ( closely match relate unrelated donor ) βthalassemia major Sickle cell anemia Hemoglobin E/βthalassemia Severe immunodeficiency disease ChediakHigashi disease WiskottAldrich syndrome Combined immunodeficiency disease ( Nezelof 's ) Hyper immunoglobulin M ( IgM ) syndrome Bare lymphocyte syndrome Chronic granulomatous disease Familial erythrohemophagocytic lymphohistiocytosis Other stem cell defect ( e.g. , osteopetrosis ) Severe immune dysregulation/autoimmune disorder Achieved transient response prior immunosuppressive therapy Chronic myelogenous leukemia Disease first chronic phase Acute myeloid leukemia Disease first remission Myelodysplastic syndrome Inborn error metabolism Histiocytosis No severe combine immunodeficiency disease Matched relate unrelated donor available high resolution DNA typing Related donor , meet follow criterion : Matched human leukocyte antigen ( HLA ) Drβ1 alleles No 1 mismatch 4 HLAA B allele Unrelated donor , meet 1 follow criterion : Marrow match HLADrβ1 allele AND 1 mismatch 4 HLAA B alleles Umbilical cord blood match 5/6 HLAA , B , DRβ1 alleles least 1 DRβ1 match AND ≥ 3x10^5 CD34+ ( Cluster differentiation 34positive ) cell per kg body weight recipient available time cryopreservation PATIENT CHARACTERISTICS : Cardiac ejection fraction ≥ 27 % Creatinine clearance ≥ 50 mL/min 24hour urine collection glomerular filtration rate DLCO ( diffusion capacity lung carbon monoxide ) ≥ 50 % predict ( correct anemia/lung volume ) PRIOR CONCURRENT THERAPY : No prior transplantation leukemia patient remain engrafted alemtuzumab need part condition regimen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>congenital amegakaryocytic thrombocytopenia</keyword>
	<keyword>Diamond-Blackfan anemia</keyword>
	<keyword>severe congenital neutropenia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>